McKinsey & Company’s Conduct and Conflicts at the Heart of the Opioid Epidemic, Hearing Before the House Committee on Oversight and Reform

Authors

Jessica Tillipman, George Washington University Law SchoolFollow

Document Type

Response or Comment

Publication Date

2022

Status

Accepted

Abstract

On April 27, 2022, Jessica Tillipman, Assistant Dean for Government Procurement Law Studies at The George Washington University Law School testified before the House Committee on Oversight and Reform regarding McKinsey & Company's potential Organizational Conflict of Interest between its contracts with the Food & Drug Administration (FDA) and its commercial, opioid manufacturer clients. Her testimony addressed the longstanding need to update and clarify the current legal framework governing Organizational Conflicts of Interest (OCIs) in the Federal Acquisition Regulation (FAR) and the importance of government contractors maintaining strong internal ethics and compliance programs.

GW Paper Series

2022-18

SSRN Link

https://ssrn.com/abstract=4109288

Recommended Citation

McKinsey & Company’s Conduct and Conflicts at the Heart of the Opioid Epidemic: Hearing Before the H. Comm. on Oversight & Reform, 117th Cong. (2022) (statement of Jessica Tillipman, Assistant Dean for Government Procurement Law Studies, The George Washington University Law School).